Adakveo, Analyst Color, Analyst Ratings, Benzinga, Biotech, GBT, Movers, NVS, Oxbryta, Paul Choi, Price Target, Trading Ideas, Upgrades, US66987V1098

Global Blood Analyst Projects More Than 60% Upside On Receding Sickle Cell Drug Concerns

Shares of Global Blood Therapeutics Inc (NASDAQ: GBT) have materially underperformed the broader biotech group, rendering its valuation attractive, according to Goldman Sachs.

Latest Ratings for GBT
DateFirmActionFromTo Jul 2020Goldman SachsUpgrad…